Evidence map›Paper›PMID 37748266›Full record

Trial reportThe American journal of emergency medicine2023

Association of substance use with outcomes in mildly ill COVID-19 outpatients.

Ruth Pobee, Tracy Cable, David Chan, Jesica Herrick, Valerie Durkalski-Mauldin, Frederick Korley, Clifton Callaway, Marina Del Rios

Open access · greenAbstract readClinical Trial
In one paragraph

Trial report in The American journal of emergency medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 8 institutions in 1 country.

Ruth PobeeUI Health/University of Illinois Chicago College of Medicine, Departments of Emergency Medicine, 808 S. Woods St., Chicago, IL 60612, USA. Electronic address: rpobee@uic.edu.
Tracy CableUniversity of Cincinnati Medical Center, Infectious Disease, 234, Goodman St Cincinnati, OH 45219, USA.
David ChanUniversity of Illinois Chicago, Department of Pharmacy Practice, 833 S Wood St, Chicago, IL 60612, USA. Electronic address: dchan@uic.edu.
Jesica HerrickUI Health/University of Illinois Chicago College of Medicine, Medicine Infectious Disease, 1740 W Taylor St, Chicago, IL 60612, USA. Electronic address: christe5@uic.edu.
Valerie Durkalski-MauldinMedical University of South Carolina, Department of Public Health Sciences, 135 Cannon St, Ste 303, Charleston, SC 29425, USA. Electronic address: durkalsv@musc.edu.
Frederick KorleyUniversity of Michigan, Departments of Emergency Medicine, 1500 E Medical Center Dr Spc 5301, Ann Arbor, MI 48109, USA. Electronic address: korley@med.umich.edu.
Clifton CallawayUniversity of Pittsburgh, Departments of Emergency Medicine, 400A Iroquois, 3600 Forbes Avenue, Pittsburgh, PA 15260, USA. Electronic address: callawaycw@upmc.edu.
Marina Del RiosUI Health/University of Illinois Chicago College of Medicine, Departments of Emergency Medicine, 808 S. Woods St., Chicago, IL 60612, USA; University of Iowa Hospitals and Clinics, Department of Emergency Medicine, Iowa, USA. Electronic address: marina-delrios@uiowa.edu.
Chicago Department of Public Health · USIllinois College · USMedical University of South Carolina · USUniversity of Cincinnati · USUniversity of Illinois Chicago · USUniversity of Iowa Hospitals and Clinics · USUniversity of Michigan · USUniversity of Pittsburgh · US

Funding

ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating CenterOT2HL156812 · NHLBI · RESEARCH TRIANGLE INSTITUTE · PI NOLEN, TRACY L, THOMAS, SONIA M · 2020 to 2024
$1270.7M
Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Clinical Coordinating Center (CCC)U24NS100659 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WILLIAM G BARSAN, Clifton W. Callaway · 2017 to 2026
$6.4M
Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Data Coordinating CenterU24NS100655 · NINDS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI VALERIE L DURKALSKI, Sharon Dziuba Yeatts · 2017 to 2026
$4.4M
NHLBI NIH HHS OT2 HL156812NINDS NIH HHS U24 NS100655NINDS NIH HHS U24 NS100659
6 · The paper itself

Abstract

backgroundSmoking, alcohol use, and non-prescription drug use are associated with worsened COVID-19 outcomes in hospitalized patients. Whether there is an association between substance use and outcomes in patients with COVID-19 who visited the Emergency Department (ED) but did not require hospitalization has not been well established. We investigated whether smoking, alcohol, and non-prescription drug use were associated with worsened COVID-19 outcomes among such patients presenting to the ED.

methodsWe conducted a secondary analysis of a clinical trial which sought to determine the effect of early convalescent plasma administration in patients presenting to the ED within 7 days of onset of mild COVID-19 symptoms. The study recruited 511 participants who were aged 50 years or older or had one or more risk factors for severe COVID-19. The primary outcome was disease progression within 15 days after randomization, which was defined as a composite of hospital admission for any reason, seeking emergency or urgent care, or death without hospitalization. Secondary outcomes included: no hospitalization within 30 days post-randomization, symptom worsening on the 5-category COVID-19 outpatient ordinal scale within 15 days post-randomization, and all-cause mortality. Substance use was categorized into either use or never use based on participant self-report. Logistic regression models were used to determine the association between substance use and outcomes.

resultsThe mean age of the 511 patients enrolled was 52 years and the majority were females (274, 54%). Approximately 213 (42%) were non-Hispanic Whites, 156 (30%) Hispanics, 100 (20%) non-Hispanic Blacks, 18 (4%) non-Hispanic Asian, 8 (1%) American Indian Alaskan, and 16 (3%) unknown race. Tobacco 152 (30%) was the most common substance use reported. Alcohol use 36 (7%) and non-prescription drug use 33 (6%) were less common. Tobacco use and non-prescription drug use were associated with an increased risk for meeting the primary outcome ((tobacco: adjusted odds ratio [aOR] =2.08; 95% confidence interval [CI]: 1.37-3.15) and (drug: aOR =2.41; 95%CI: 1.17-5.00)) and increased risk for symptom worsening on the 5-category COVID-19 outpatient scale ((tobacco: aOR = 1.62; 95%CI: 1.09-2.42) and (drug: aOR = 2.32 95% CI: 1.10-4.87)) compared to non-use after adjusting for age, sex, plasma administration, and comorbidity.

conclusionTobacco and non-prescription drug use but not alcohol use were associated with worsened COVID-19 outcomes in patients who did not require hospitalization on their initial presentation. Future studies should determine the quantity, duration, and type of drug/tobacco use that may worsen COVID-19.

Indexed as

COVID-19Substance-Related DisordersCOVID-19 SerotherapyFemaleHospitalizationHumansMaleMiddle AgedNonprescription DrugsOutpatientsSymptom Flare UpNonprescription DrugsAlcoholCOVID-19Disease progressionDrugHospitalizationSmoking

Identifiers

PMID37748266
PMCPMC10841661
OpenAlexW4386852170

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.